A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer

Clinical Lung Cancer

Volumn 12, Issue 3, 2011, Pages 187-191

  Spigel, David R ^a,b   Greco, F Anthony ^a,b   Burris III, Howard A ^a,b   Shipley, Dianna L ^b   Clark, Bobby L ^a   Whorf, Robert C ^c   Arrowsmith, Edward R ^d   Hainsworth, John D ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b PLLC   (United States)

^c Sarah Cannon Research Institute/Florida Cancer Specialists   (United States)

^d Chattanooga Oncology and Hematology Associates PC   (United States)

Author keywords

Hematologic toxicity; Higher dose; Phase II; Small cell lung cancer; Topotecan; Weekly

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER FATIGUE; CANCER GROWTH; CANCER PAIN; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959610811     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.016     Document Type: Article

References (15)

1. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-67. (Pubitemid 29075255)
2. Bhoola SM, Coleman RL, Herzog T, et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 2004; 95:564-9. (Pubitemid 39592522)
3. Frasci G, Panza N, Comella P, et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study. Ann Oncol 1999; 10:355-8. (Pubitemid 29217230)
4. Gelderblom H, Sparreboom A, de Jonge MJ, et al. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer. Br J Cancer 2001; 85:1124-9. (Pubitemid 33052310)
5. Homesley H, Benigno B, Williams J, et al. A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol Oncol 2002; 87:171-7. (Pubitemid 36044082)
6. Homesley HD, Hall DJ, Martin DA, et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001; 83: 394-9. (Pubitemid 33033085)
7. Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology 2007; 73:177-84. (Pubitemid 351630047)
8. Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004; 95: 686-90. (Pubitemid 39592538)
9. Morris RT. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 2003; 90:S34-8. (Pubitemid 37103164)
10. Rose PG, Smrekar M, Haba P, et al. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol 2005; 99:714-9. (Pubitemid 41686557)
11. Stathopoulos GP, Malamos NA, Aravantinos G, et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2006; 60:123-8.
12. Shipley DL, Hainsworth JD, Spigel DR, et al. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)-A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2006; 24:7083.
13. Shipley D, Spigel DR, Hainsworth JD, et al. Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC). J Clin Oncol 2008; 26(suppl) abstract 19073. Available at www.asco.org. Accessed April 14, 2011.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.